CD274 and neoplasm: Additionally, a separate preclinical study has demonstrated that the novel oncolytic virus CF33, in combination with PD-L1 monoclonal antibody, elicits sustained anti-tumor immune responses and prolongs the survival of mice in a colon cancer model (Kim et al., 2021).